Treatment Options for Nonmetastatic CRPC

EP: 1.Incidence and Risk Factors of Prostate Cancer

EP: 2.Presentation and Diagnosis of Prostate Cancer

EP: 3.Screening and Diagnosis of Prostate Cancer

EP: 4.Prostate Cancer Prognosis and Risk Stratification

EP: 5.Differences in the Treatment of Patients with Prostate Cancer

EP: 6.Prostate Cancer: Treatment Decision-Making and the Role of Guidelines

EP: 7.Informing Prostate Cancer Treatment Decisions with Clinical Trials and Real-World Evidence

EP: 8.Systemic Therapy for Prostate Cancer

EP: 9.Androgen Deprivation Therapy for Prostate Cancer

EP: 10.Metastatic Hormone-Sensitive Prostate Cancer Treatment Options

EP: 11.Overview of Castrate-Resistant Prostate Cancer (CRPC)

Now Viewing

EP: 12.Treatment Options for Nonmetastatic CRPC

EP: 13.Treatment Approach for Patients With Metastatic CRPC

EP: 14.The Role of Combination Therapy in mCRPC

EP: 15.Improving Clinical Trials in Prostate Cancer

EP: 16.Educating Patients and Caregivers About Prostate Cancer

EP: 17.Advice for Patients With Prostate Cancer

This is a synopsis of an Educated Patient Sound Bites series featuring Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute; Rashid K. Sayyid, MD, MSc, of the University of Toronto; and Reginald Tucker-Seeley, MA, ScM, ScD, of ZERO Prostate Cancer.

Dr Rashid K. Sayyid defines nmCRPC [non-metastatic castration-resistant prostate cancer] as evidence of castration resistance without metastases on CT or bone scan. He notes recent progress in nmCRPC treatment, with FDA approval of second-generation antiandrogens apalutamide, enzalutamide, and darolutamide along with continued androgen deprivation therapy (ADT). Approvals were based on the phase 3 ARAMIS, PROSPER, and SPARTAN trials respectively.

The ARAMIS trial randomized patients with nmCRPC with rapidly rising prostate-specific antigen (PSA) to darolutamide or placebo plus ADT. Metastasis-free survival increased from 18 to 40 months with darolutamide, reducing death risk by 31%. Similarly, the PROSPER trial using enzalutamide improved metastasis-free and overall survival by 11 months. Finally, the SPARTAN trial with apalutamide extended metastasis-free survival by 2 years and overall survival over 1 year.

In summary, Dr Rashid K. Sayyid reviews recent progress in treating non-metastatic castrate-resistant prostate cancer with second-generation antiandrogens apalutamide, enzalutamide, and darolutamide. The phase 3 ARAMIS, PROSPER, and SPARTAN trials supported FDA approval.

*Video synopsis is AI-generated and reviewed by CURE editorial staff.